The Engineering of Natural Killer Cells as an Emerging Adoptive Cancer Immunotherapy

Abstract

T cells and but need to be genetically modified to recognize and kill targets. This can be achieved by introducing CARs into NK cells and cell lines. Scientists also face the challenge of properly manufacturing engineered NK cells. If successful, CAR NK cells could be safer, cheaper, easier to produce, and more widely applicable than T cells. This review focuses on recent advances in NK cell engineering and discusses how NK cells contribute to new immunotherapeutic approaches for treatment against refractory hematological malignancies.